Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?

Table 1

Patient demographics	𝑛=109
Male, 𝑛 (%)	59 (54)
Median BSA (range), m^2	2.05 (1.36–2.84)
Diagnosis	𝑛 (%)
Follicular lymphoma	70 (64)
Marginal zone lymphoma	11 (10)
Unspecified low-grade lymphoma	9 (8)
Mantle cell lymphoma	10 (9)
CLL/SLL	6 (5.5)
Mucosa-associated lymphoid tissue	3 (2.8)
Baseline laboratory parameters	k/𝜇L (range)
Median lymphocyte count	1.24 (0.04–8.21)
Median WBC	5.38 (1.34–13.07)
Premedications
Acetaminophen	99%
Diphenhydramine	75%
Cetirizine	23%
Corticosteroids	8.8%
Rituximab
Median dose, mg	750 (410–1090)
Median no. doses	6 (1–20)
Mean infusion time, min	90 (85–97)